Download Free Medical Clinical Trials: The Drug Development Process PowerPoint Presentation

Clinical Trials: The Drug Development Process PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Drug Development, which is titled "Clinical Trials: The Drug Development Process", to know about categories of clinical trials, stages of the Drug Development Process, and phases of a clinical trial (FDA and ICH).

Tags : Drug Development, Clinical Trials, Process, categories, stages, phases, FDA, ICH

Published on : Jul 20, 2021 | Views : 2914 | Downloads : 11

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Research 101sponsored by
Slide 2-

Conflict of Interest Disclosure Conflicts of Interest A Conflict of Interest occurs when an individual has an opportunity to affect educational content about healthcare products or services of a commercial interest with which she/he has a financial relationship. There is no conflict of interest for this presentation. Commercial Support No commercial support for this seminar Non-Endorsement of Products Non-applicable
Slide 3-

Clinical Trials: The Drug Development Process May 26, 2020 Janie Gardner, MS, CCRP, CIM Clinical Research Development
Slide 4-

Key Takeaways Two major categories of clinical trials Stages of the Drug Development Process Phases of a clinical trial (FDA and ICH)
Slide 5-

Clinical Trials A Clinical Trial is a special type of Clinical Research that evaluates the effects of an intervention ( or no intervention) on biomedical or health –related outcomes. Two broad types of Clinical Trials Observational Interventional There are many study designs to choose from within these two broad categories of observational and interventional studies.
Slide 6-

Observational studies, -also called epidemiological studies, are those where the investigator does not act upon study participants, but instead observes natural relationships between factors and outcomes. These studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods. Common study designs include: Case-control, case-crossover, retrospective and prospective cohorts.
Slide 7-

Interventional studies -also called experimental studies are those where the researcher intervenes or interacts with the participants/ subjects at some point during the study. These studies are often prospective and are specifically tailored to evaluate direct impacts of treatment (therapeutic) or preventive measures on disease. Two Major Types of Interventional Studies Controlled clinical trials in which individual subjects are assigned to one or another of the competing interventions, or Community interventions, in which an intervention is assigned to an entire group.
Slide 8-

Two Major Study Designs of Interventional Studies Experimental or Randomized Controlled Trial (RCT) * considered the most robust of the evaluation methodologies. By randomly allocating the intervention among eligible beneficiaries, the assignment process itself creates comparable treatment and control groups that are statistically equivalent to one another, given appropriate sample sizes. Non- Randomized or Quasi-experimental research is an empirical study, almost like an experimental design but without random assignment. Quasi-experimental designs typically allow the researcher to control the assignment to the treatment condition but using some criterion other than random assignment (e.g., an eligibility cutoff mark). The randomized controlled trial is considered the gold standard for today’s clinical investigations.
Slide 9-

Site Selection
Slide 10-

Drug Development IND Trial A drug development plan describes all aspects of the development of a product from the target product profile through post-approval activities. The plan is usually prepared prospectively and updated as the development progresses and new information becomes available. Drug development plan is ideally a logical, step-wise process in which information from small early studies is used to support and plan later larger, more definitive studies.
Slide 11-

Pre-clinical Stage of Drug Development Discovery Product Activity Safety Studies Toxicity Manufacturing Quality Stability
Slide 12-

Discovery Discovery typically begins with basic research where researchers seek to understand the processes behind a disease, often at a cellular or molecular level. These new insights into disease processes and pathways can lead to identification of targets for new treatments For example, a gene or protein essential to the disease process that a new treatment could interfere with, for example, by blocking an essential receptor.
Slide 13-

Once targets are identified , researchers may identify molecular compounds to find possible beneficial effects against target/ disease existing treatments that have unanticipated effects. new technologies that provide new ways to target medical products to specific sites within the body or to manipulate genetic material. 2 – 10 years
Slide 14-

Preclinical Testing Novel drug products undergo laboratory and animal testing to answer basic questions about safety. Manufacturer completes synthesis and purification of the drug and conducts stability studies. Safety and drug activity tests are conducted Using computerized models, Cells and Animals 3 – 6 years
Slide 15-

FDA Investigational New Drug Application Request submitted to the FDA to allow human exposure to the experimental drug Request for exemption from the FDA to ship an unapproved product through interstate commerce Creates an ongoing file at the FDA containing data on the investigational product as it passes through the development process (“living application”)
Slide 16-

Preparing for an IND Submission Key Elements for and IND(a) Proof-of-concept scientific data Should include considerations of product activity, ability to replicate results and a reasonable explanation how the product will prevent, diagnose, treat or cure disease. A target clinical Indication Clinical plan/ protocol Animal toxicology data Usually obtained in two species that supports the dose, dosing schedule, administration, and study duration proposed in the clinical protocol. Manufacturing process Provides evidence that product is manufactured according to GMP, including analytical tests results confirming the quality of the product several batches of the product. Stability Information Data demonstrating the stability of the drug, under defined storage conditions, or the period of use for the clinical trial
Slide 17-

Good Manufacturing Practices FDA 21 CFR Part 210. Current Good Manufacturing Practice in Manufacturing Processing, packing, or Holding of Drugs. 21 CFR Part 211. Current Good Manufacturing Practice for Finished Pharmaceuticals. ICH Quality guidelines ( ICH Q1 A – Q14) Good Laboratory Practices ( Non- clinical laboratories) FDA 21 CFR Part 58. Good Laboratory Practice for Nonclinical Laboratory Studies ICH Safety guidelines ( ICH S1A – S12)
Slide 18-

Clinical Trials 6 – 8 years
Slide 19-

Clinical Research FDA Requirements (Oversight)
Slide 20-

Phases of a Clinical Drug Trial Phase 0 – Phase IV
Slide 21-

Phase 0 Clinical Trial (Micro-dosing) Question: Does it affect target? Defining Characteristics Duration : Usual <7 days Population: < 10 subjects Study Design: Sub -therapeutic dose to obtain preliminary pharmaco-kinetic and pharmaco-dynamic data in humans Focus: Gives no safety or efficacy information Allows product to be evaluated on human data instead of animal Supports decision to go forward with development - or not No therapeutic intent
Slide 22-

Phase I Clinical Trial ( PK, Safety, Toxicity) Question: Is this drug candidate safe? Defining Characteristics Duration : Short term – rarely over 30 days Population: 20 – 50 Normal healthy volunteers Occasionally, where the drug is to be used in patients with a particular disease (e.g., cancer) these patients may participate as subjects. Study Design: Dose escalation studies to establish Maximum Tolerated Dose (MTD) Focus: Safety and Tolerability in Humans Studies of pharmacokinetics, bioavailability, bioequivalence, metabolism and toxicity
Slide 23-

Phase II Clinical Trials (Dose Response) Question: Does this drug candidate work? Defining Characteristics Duration: Short to medium - < a year Population: Few hundred (200 – 500) volunteers with the target disease Design: Randomized blinded trials, strict eligibility criteria Usually not compared to standard of care therapy Focus: Dose estimate for subsequent studies, establish effectiveness for a specific population and disease, collect additional safety information Minimum Effective Dose
Slide 24-

Phase III Trials (Pivotal Trial) Question: Is this drug candidate more effective than existing treatment options? Defining Characteristics Duration: Parallels anticipated treatment – often can be years Population: Hundreds to thousand in populations the investigational product is intended to treat Design: Expanded randomized double –blind controlled trials, broader subject eligibility criteria - are often multi- center Focus: Additional safety information and efficacy data with a selected dose Risks/benefit analysis, dosing intervals, labeling information, safety profiles
Slide 25-

Phase IV Clinical Trials (Post Market Approval) Question: How does this new drug perform in general use over time? Defining Characteristics Duration : Years Population: Hundred to thousands May involve additional age or ethnic groups Focus: Additional safety /efficacy data Identify rare side effects Familiarize physicians with the compound Patient satisfaction
Slide 26-

FDA Phases of Drug Development (ICH Types of Clinical Drug Trials) ICH E8
Slide 27-

ppt slide no 27 content not found
Slide 28-

FDA Review Stages of FDA Review Pre- IND Review FDA reviews results of preclinical testing in laboratory animals and the plan to carry testing into human populations. At this stage, the FDA decides whether it is reasonably safe for the company to move forward with testing the drug in humans. IND Review The FDA review team has 30 days to review the original IND submission. The process protects volunteers who participate in clinical trials from unreasonable and significant risk in clinical trials. Clinical Trials Review Two commonly scheduled meetings with the FDA during clinical trials in the drug development process. End of Phase II – safety and efficacy data from phases I and II are reviewed and the FDA and sponsors come to an agreement how large scale studies in Phase III should proceed. Pre- NDA Submission – is held to ensure the submission is well-organized, complete and properly formatted. Also an opportunity to obtain the FDA thoughts on your product application’s readiness for filing and likelihood of approval.
Slide 29-

FDA BIMO Program is A comprehensive program of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA regulated research BIMO Compliance Programs include: Sponsors, Monitors and Contract research organizations Institutional Review Boards (IRBs Clinical investigators Nonclinical (animal) laboratories, and bioequivalence analytical laboratories BIMO inspections can be conducted by FDA at any time during a clinical study, either “for cause,” near the time of study closure, or during agency review of a marketing application. FDA BIMO Compliance Program FDA Oversight
Slide 30-

MedWatch is FDA’s medical product safety reporting program for health professionals, patients and consumers. Serves two main purposes. It offers AERS tools that allow medical professionals and the public to report medication errors and medical product injuries. MedWatch also provides clinical information about prescription and over-the-counter drugs, biologics, medical and radiation-emitting devices, and special nutritional products, such as medical foods, dietary supplements, and infant formulas. FDA Post-market Safety Surveillance Program MedWatch
Slide 31-

MedWatch Forms Voluntary Report forms for observed or suspected adverse events or product problem Form 3500 for Health professionals, Form 3500B for Consumers and Patients Mandatory reporting for use by IND reporters, manufacturers, distributors, importers, user facilities personnel. Form 3500A – Effective June 15, 2015, All adverse event reports for approved drugs are required to be submitted by a manufacturer to FAERS electronically, specifically using theelectronic format that replicates form FDA 3500A. For approved drugs, manufacturers are required by law to submit to FDA an individual case safety report (ICSR) for any adverse event that is reported to them, regardless of causality. In its evaluation of the event, the manufacturer must decide whether the event was serious and unexpected, serious and expected, or non-serious.
Slide 32-

ppt slide no 32 content not found
Slide 33-

Useful Resources Categories of clinical studies – https://clinicaltrials.gov/ct2/about-studies/learn Drug development process – https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development- process Phases of Clinical Trials https://www.centerwatch.com/clinical-trials/overview Phase 0 clinical trials - https://journals.lww.com/oncology- times/Fulltext/2006/08100/FDA_Introduces_New_Phase_0_for_Clinical_Trials_.6.aspx FDA Review https://www.fda.gov/drugs/drug-information-consumers/fdas-drug-review-process-continued
Slide 34-

MedWatch https://www.accessdata.fda.gov/scripts/medwatch/index.cfm BIMO https://www.fda.gov/science-research/clinicaltrials-and-human-subject- protection/bioresearch-monitoring-program-bimo